NO20022500L - Fremgangsmåte ved fremstilling av virus eller viralproteiner til anvendelse i vaksiner - Google Patents

Fremgangsmåte ved fremstilling av virus eller viralproteiner til anvendelse i vaksiner

Info

Publication number
NO20022500L
NO20022500L NO20022500A NO20022500A NO20022500L NO 20022500 L NO20022500 L NO 20022500L NO 20022500 A NO20022500 A NO 20022500A NO 20022500 A NO20022500 A NO 20022500A NO 20022500 L NO20022500 L NO 20022500L
Authority
NO
Norway
Prior art keywords
virus
viruses
vaccines
production
human cells
Prior art date
Application number
NO20022500A
Other languages
English (en)
Other versions
NO333527B1 (no
NO20022500D0 (no
Inventor
Maria Grazia Pau
Alphonsus Gerardus C Uytdehaag
Govert Johan Schouten
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022500(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of NO20022500D0 publication Critical patent/NO20022500D0/no
Publication of NO20022500L publication Critical patent/NO20022500L/no
Publication of NO333527B1 publication Critical patent/NO333527B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36251—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20022500A 1999-11-26 2002-05-27 Fremgangsmate ved fremstilling av virus eller viralproteiner til anvendelse i vaksiner. NO333527B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203983A EP1103610A1 (en) 1999-11-26 1999-11-26 Production of vaccines from immortalised mammalian cell lines
PCT/NL2000/000862 WO2001038362A2 (en) 1999-11-26 2000-11-24 Production of vaccines

Publications (3)

Publication Number Publication Date
NO20022500D0 NO20022500D0 (no) 2002-05-27
NO20022500L true NO20022500L (no) 2002-07-26
NO333527B1 NO333527B1 (no) 2013-07-01

Family

ID=8240914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022500A NO333527B1 (no) 1999-11-26 2002-05-27 Fremgangsmate ved fremstilling av virus eller viralproteiner til anvendelse i vaksiner.

Country Status (20)

Country Link
EP (3) EP1103610A1 (no)
JP (1) JP4331432B2 (no)
KR (2) KR100683374B1 (no)
CN (1) CN1306033C (no)
AT (1) ATE286537T1 (no)
AU (2) AU775966B2 (no)
BR (1) BR0015846A (no)
CA (1) CA2392653C (no)
DE (1) DE60017234T3 (no)
DK (1) DK1108787T4 (no)
EA (1) EA006136B1 (no)
ES (1) ES2235770T5 (no)
IL (2) IL149788A0 (no)
MX (1) MXPA02005237A (no)
NO (1) NO333527B1 (no)
NZ (1) NZ527942A (no)
PT (1) PT1108787E (no)
SI (1) SI1108787T2 (no)
WO (1) WO2001038362A2 (no)
ZA (1) ZA200204078B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000326A1 (en) 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
JP5503096B2 (ja) 2001-01-19 2014-05-28 ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ 感受性哺乳動物において気道疾患を引き起こすウイルス
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2002351444B2 (en) * 2001-12-07 2008-02-21 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
AU2002225509A1 (en) * 2001-12-07 2003-06-17 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
CA2470579C (en) * 2001-12-17 2012-03-06 Crucell Holland B.V. Production of f(ab')2 fragments in mammalian cells
JP4553589B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー 組換えパラインフルエンザウイルス発現系とメタニューモウイルスから得られる異種抗原を含むワクチン
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
NZ538808A (en) * 2002-11-08 2008-03-28 Crucell Holland Bv Vaccines against west nile virus
WO2004056979A2 (en) * 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
AU2004273776B2 (en) * 2003-04-25 2010-07-08 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
AU2004278517B2 (en) 2003-10-02 2010-04-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
ES2456015T3 (es) * 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
ES2432655T3 (es) * 2004-09-09 2013-12-04 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados con antígenos de vacunas
JP2006090864A (ja) * 2004-09-24 2006-04-06 Denka Seiken Co Ltd ワクチン中の特定成分の含量を求める方法
CN101128598B (zh) 2004-12-08 2013-04-24 米迪缪尼有限公司 生产流感疫苗组合物的方法
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
KR101274790B1 (ko) * 2005-07-22 2013-06-13 크루셀 홀란드 비.브이. 코로나바이러스 생산용 세포주
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
HUE032608T2 (en) 2006-07-14 2017-10-30 Patheon Holdings I B V An improved method for cell culture
US8361788B2 (en) * 2007-07-03 2013-01-29 Transgene S.A. Immortalized avian cell lines comprising E1A nucleic acid sequences
WO2009074318A2 (en) * 2007-12-13 2009-06-18 Roche Diagnostics Gmbh Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
KR20100135766A (ko) * 2008-03-18 2010-12-27 노파르티스 아게 인플루엔자 바이러스 백신 항원 제조의 개선
US8163523B2 (en) 2008-06-11 2012-04-24 Flugen, Inc. Cell-based systems for producing influenza vaccines
CA2728477C (en) * 2008-07-15 2017-02-28 Crucell Holland B.V. Scalable process for culturing per.c6 cells and producing products therefrom
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
WO2010046335A1 (en) * 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
RS53377B (sr) 2009-07-16 2014-10-31 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju vakcine
US20130203151A1 (en) 2010-04-26 2013-08-08 Scott Balsitis Production of alphavirus replicon particles in packaging cells
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
CN104105504A (zh) 2011-10-11 2014-10-15 诺华股份有限公司 重组多顺反子核酸分子
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
CN102526720B (zh) * 2012-01-11 2013-12-11 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒疫苗的制备方法
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
CN102631673A (zh) * 2012-04-17 2012-08-15 金宇保灵生物药品有限公司 口蹄疫疫苗浓缩纯化方法
KR20210095233A (ko) 2013-03-15 2021-07-30 젠자임 코포레이션 고-밀도 세포 뱅킹 방법
US20160100570A1 (en) 2014-09-18 2016-04-14 Genzyme Corporation Ultra-high density cell banking methods
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
SG11201704690TA (en) 2014-12-17 2017-07-28 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
WO2016097218A1 (en) 2014-12-17 2016-06-23 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
CN108027371B (zh) * 2015-07-07 2020-08-18 思齐乐 流感效力试验
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
WO2019090238A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
BR112020010883A2 (pt) 2017-12-01 2020-11-10 Encoded Therapeutics, Inc. proteínas de ligação a dna engenheiradas
KR20200015323A (ko) 2018-08-03 2020-02-12 에릭스바이오(주) 바이러스 치료 장치 또는 백신 제조 장치
EP4223320B1 (en) 2018-10-12 2025-06-18 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
CA3118936A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
MX2021011913A (es) 2019-05-08 2021-12-15 Takeda Vaccines Inc Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
SG11202113048SA (en) 2019-05-29 2021-12-30 Encoded Therapeutics Inc Compositions and methods for selective gene regulation
MX2023000968A (es) 2020-08-06 2023-03-01 Fundacion Para La Investig Medica Aplicada Particulas virales para usarse en el tratamiento contra tauopatias tales como enfermedad de alzheimer mediante terapia genica.
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
AU2021358413A1 (en) 2020-10-09 2023-05-25 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
AU2022378524A1 (en) 2021-10-28 2024-05-02 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
US20250381261A1 (en) 2022-02-09 2025-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547779A (en) * 1968-12-18 1970-12-15 Merck & Co Inc Process for producing purified concentrated influenza virus
US5192539A (en) * 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines

Also Published As

Publication number Publication date
MXPA02005237A (es) 2003-09-22
NO333527B1 (no) 2013-07-01
JP2003516733A (ja) 2003-05-20
AU2004203642A1 (en) 2004-09-02
EP1108787B2 (en) 2008-12-10
SI1108787T2 (sl) 2009-06-30
EP1108787B1 (en) 2005-01-05
ZA200204078B (en) 2003-08-22
AU775966B2 (en) 2004-08-19
KR20060107868A (ko) 2006-10-16
DK1108787T3 (da) 2005-04-04
EP1108787A2 (en) 2001-06-20
DK1108787T4 (da) 2009-04-14
KR20020064910A (ko) 2002-08-10
DE60017234T2 (de) 2005-12-08
IL149788A0 (en) 2002-11-10
SI1108787T1 (en) 2005-06-30
DE60017234D1 (de) 2005-02-10
ES2235770T5 (es) 2009-05-01
BRPI0015846B1 (pt) 2001-05-31
WO2001038362A2 (en) 2001-05-31
CN1306033C (zh) 2007-03-21
JP4331432B2 (ja) 2009-09-16
EA006136B1 (ru) 2005-10-27
ATE286537T1 (de) 2005-01-15
EP1514937A1 (en) 2005-03-16
NO20022500D0 (no) 2002-05-27
BRPI0015846B8 (no) 2021-05-25
ES2235770T3 (es) 2005-07-16
DE60017234T3 (de) 2009-07-09
EA200200604A1 (ru) 2002-12-26
EP1108787A3 (en) 2001-08-29
NZ527942A (en) 2004-07-30
IL149788A (en) 2010-12-30
EP1103610A1 (en) 2001-05-30
BR0015846A (pt) 2002-07-16
KR100683374B1 (ko) 2007-02-15
PT1108787E (pt) 2005-04-29
WO2001038362A3 (en) 2002-02-14
AU2557201A (en) 2001-06-04
HK1057236A1 (en) 2004-03-19
CA2392653A1 (en) 2001-05-31
CA2392653C (en) 2011-03-29
CN1433472A (zh) 2003-07-30

Similar Documents

Publication Publication Date Title
NO20022500L (no) Fremgangsmåte ved fremstilling av virus eller viralproteiner til anvendelse i vaksiner
AU2002338666B2 (en) Multiplication of viruses in a cell culture
JP4787156B2 (ja) 付着または非付着の鳥類細胞系を用いた、ポックスウィルスの作製法
RU2314344C2 (ru) Способ крупномасштабного производства вирусного антигена
US20050118140A1 (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
KR20120033334A (ko) 백신 제조를 위한 고역가 폴리오바이러스의 제조
RU2011148791A (ru) Иммортализованные линии клеток птиц и их применение
AR033993A1 (es) Metodo para producir reovirus infeccioso y de mamifero, y composicion de reovirus
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
CN108611351B (zh) ID1基因的sgRNA、ID1基因的敲除方法、BHK-21细胞系及其用途
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
Igarashi A mutant of chikungunya virus isolated from a line of Singh's Aedes albopictus cells by plaque formation on virus-sensitive cloned cells obtained from another Singh's A. albopictus cell line
Mazurkova et al. Optimization of Reproduction Conditions of the Vaccine Cold-Adapted Recombinant Strains of Influenza Virus in Roller-Cultivated MDCK Cells
HK1022496A1 (en) Immortalized cell lines for virus growth
HK1022496B (en) Immortalized cell lines for virus growth
RU93048664A (ru) Способ суспензионного культивирования филовирусов в клеточных культурах на микроносителях
RU95117008A (ru) Способ получения живой коревой вакцины

Legal Events

Date Code Title Description
MK1K Patent expired